Registered title, quoted from ClinicalTrials.gov
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 26 hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 26
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Study siteAffiliated Hospital of Xuzhou Medical University徐州医科大学附属医院XuzhouHospital page
- Study siteBeijing Chest Hospital首都医科大学附属北京胸科医院BeijingHospital page
- Study siteChina-Japan Friendship Hospital中日友好医院BeijingHospital page
- Study siteFirst Affiliated Hospital of Nanchang University南昌大学第一附属医院NanchangHospital page
- Study siteFirst Affiliated Hospital of Soochow University苏州大学附属第一医院SuzhouHospital page
- Study siteFirst Affiliated Hospital of Sun Yat-sen University中山大学附属第一医院GuangzhouHospital page
- Study siteFirst Affiliated Hospital, Zhejiang University浙江大学医学院附属第一医院HangzhouHospital page
- Study siteFirst Hospital of Jilin University吉林大学第一医院ChangchunHospital page
- Study siteFourth Hospital of Hebei Medical University河北医科大学第四医院ShijiazhuangHospital page
- Study siteHarbin Medical University Cancer Hospital哈尔滨医科大学附属肿瘤医院HarbinHospital page
- Study siteHenan Cancer Hospital河南省肿瘤医院ZhengzhouHospital page
- Study siteHunan Cancer Hospital湖南省肿瘤医院ChangshaHospital page
- Study siteLinyi Cancer Hospital临沂市肿瘤医院LinyiHospital page
- Study siteNanjing Drum Tower Hospital南京鼓楼医院NanjingHospital page
- Study siteNorthern Jiangsu People's Hospital江苏省苏北人民医院YangzhouHospital page
- Study siteShandong Cancer Hospital and Institute山东省肿瘤医院JinanHospital page
- Study siteShanghai East Hospital, Tongji University同济大学附属东方医院ShanghaiHospital page
- Study siteShanghai Pulmonary Hospital上海市肺科医院ShanghaiHospital page
- Study siteSichuan Cancer Hospital四川省肿瘤医院ChengduHospital page
- Study siteTaizhou Hospital, Wenzhou Medical University温州医科大学附属台州医院TaizhouHospital page
- Study siteTianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院TianjinHospital page
- Study siteTianjin Medical University General Hospital天津医科大学总医院TianjinHospital page
- Study siteUnion Hospital华中科技大学同济医学院附属协和医院WuhanHospital page
- Study siteWest China Hospital四川大学华西医院ChengduHospital page
- Study siteXiangya Hospital中南大学湘雅医院ChangshaHospital page
- Study siteZhejiang Cancer Hospital浙江省肿瘤医院HangzhouHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07195695, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 5
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (5 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Histology and tumor sample: Histologically confirmed diagnosis of primary NSCLC
Inclusion criterion 5
Eastern Cooperative Oncology Group (ECOG) score of 0 or 1
Inclusion criterion 9
Previous or concomitant malignancies within the last 3 years, except certain effectively treated cancers
Exclusion criterion 10
Male or female patients. Women of childbearing potential (WOCBP) must be ready and able to use dual highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the patient information and in the study protocol
Inclusion criterion 3
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; blood tests: counts, liver and kidney function; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07195695, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion criteria:
- Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial
- Patients must be ≥18 years old or over the legal age of consent in their country
- Male or female patients. Women of childbearing potential (WOCBP) must be ready and able to use dual highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the patient information and in the study protocol
- HER2 mutation: Documented Tyrosine kinase domain (TKD) activating Human epidermal growth factor receptor 2 (HER2) mutations
- Histology and tumor sample: Histologically confirmed diagnosis of primary NSCLC
- An archival tumor tissue sample must be submitted to the central laboratory after inclusion of the patient to retrospectively confirm the HER2 status
- Staging: Pretherapeutic classification not exceeding Stage IIIB
- Performance status and organ function:
- Eastern Cooperative Oncology Group (ECOG) score of 0 or 1
- Adequate organ function based on laboratory values Further inclusion criteria apply.
Exclusion criteria:
- Diagnosis of NSCLC with mixed histology/positive neuroendocrine markers (synaptophysin/CD56)
- Major surgery (major according to the investigator's assessment) performed within 4 weeks prior to randomization
- Treatment with radiation therapy for primary NSCLC
- Co-occurring actionable mutation with approved targeted therapy (e.g. Epidermal growth factor receptor (EGFR) or Anaplastic lymphoma kinase (ALK))
- Any investigational drug within 5 half-lives of the compound or any of its related material, if known
- History or presence of
- Active or known pre-existing or history of non-infectious interstitial lung disease/pneumonitis
- Active infectious disease requiring systemic therapy
- Uncontrolled gastrointestinal disorders affecting drug intake/absorption
- Previous or concomitant malignancies within the last 3 years, except certain effectively treated cancers
- Significant and/or uncontrolled cardiovascular abnormalities, QT interval corrected for heart rate by Fridericia formula (QTcF) >470 msec, or ejection fraction <50% Further exclusion criteria apply.
Quoted from ClinicalTrials.gov, NCT07195695, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07195695, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.